London, United Kingdom, March 15, 2016 --(PR.com
)-- Running for over a decade, the established ADMET conference and exhibition will play host to an audience of DMPK experts, providing a platform to discuss the current state of the ADMET field.
Day one of the event will cover ADME/PK: Optimisation for drug design and discovery as well as translating non-clinical ADME data to the clinic. Day Two of the event will focus on the topics of linking PK with safety as well as improving drug-drug interaction.
The session focusing on linking PK with safety will begin with an opening address from Friedemann Schmidt, Senior Scientist, Preclinical Safety, Sanofi-Aventis. Schmidt will open the session with his presentation entitled ‘Computational drug hazard assessment: From ADMET prediction towards organ toxicity.’ This address will provide insight into current preclinical in silico toxicology; ADMET modelling, leading to quantitative structure-toxicity relationships as well as analysing and predicting pre-clinical toxicity based on target interaction profiles.
Another highlight of the day will feature Thierry Lave, Head DMPK and TOX Project Leaders and Modelling & Simulation from Roche Pharmaceuticals. His presentation entitled ‘Translational modelling in support to efficacy and safety assessments’ will hone in on the value of model-based approaches for supporting safety assessments during drug discovery and development stages. As well as this Mr Lave will look at the requirements for translational PKPD and the value of integrating translational PKPD in early development.
Joining Sanofi-Aventis and Roche Pharmaceuticals on the discussion of Linking PK with safety includes leading industry figures from: Vertex Pharmaceuticals, UCB and University of Hertfordshire.
To download the full agenda with all sessions, speakers and their topics, please visit www.admet-event.com/prcom
Highlights of 2016:
• Understand the drug-to-drug interaction in combination therapy, and ADMET study’s role in personalised medicine
• Discover application of PBPK to drug development in rare diseases
• Review the role of drug transporters in drug delivery to CNS diseases
• Learn about better models for understanding, predicting and avoiding drug induced liver injury
• Discuss in silico approaches to evidence-based mechanistic modelling
• Analyse early dose predictions – a valuable tool in risk assessment and optimisation of small molecules
• Network with industry-leading experts within the ADME and PK field - A list of past attendees can be found in the download section of the event website to give an insight of who might be attending the 2016 event. Visit www.admet-event.com/prcom
For those interested in attending, there is currently an early bird offer available saving £300 off of the conference price which expires on the 31st of March.
ADMET 2016 is sponsored by Corning and Sekisui XenoTech.
For sponsorship enquiries, contact Alia Malick on +44 (0) 207 827 6168 or email@example.com
For delegate enquiries, contact Matthew Apps on +44 (0) 207 827 6093 or firstname.lastname@example.org
For media enquiries, contact Zoe Gale on +44 (0) 207 827 6132 or email@example.com
11th annual ADMET conference and exhibition
13-14 June 2016
Contact e-mail: firstname.lastname@example.org
Contact tel: +44 (0) 207 827 6093
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk